• Contact
  • Privacy Policy
  • Advertise With Us
  • Login
  • Register
Your Trading Edge Magazine
Advertisement
  • Home
  • Feature
    • Market Commentary
    • Expert Advice
    • Columns
  • Trading
    • Shares and Trading
    • Technical Analysis
    • Trading Mindset
  • Crypto News
  • Finance
  • Subscribe
No Result
View All Result
  • Home
  • Feature
    • Market Commentary
    • Expert Advice
    • Columns
  • Trading
    • Shares and Trading
    • Technical Analysis
    • Trading Mindset
  • Crypto News
  • Finance
  • Subscribe
No Result
View All Result
Your Trading Edge Magazine
No Result
View All Result

UBS reveals a biotech stock that can nearly double from here

January 20, 2023
in Trading
Reading Time: 2 mins read
A A
0
UBS reveals a biotech stock that can nearly double from here
0
SHARES
4
VIEWS
ShareShareShareShareShare

Shares of CureVac BV (NASDAQ: CVAC) have already almost doubled year-to-date but a UBS analyst says the stock still has a lot more room to the upside.

CureVac stock could gain close to 100%

On Thursday, Eliana Merle turned bullish on the biopharmaceutical firm and sharply increased her price objective to $18 that represents close to another 100% upside from here.   


Are you looking for fast-news, hot-tips and market analysis?

Sign-up for the Invezz newsletter, today.

The upgrade arrives only weeks after the German company reported positive preliminary data for its joint COVID-19 and flu mRNA vaccine. Her note reads:

In our view, as the first data of the 2nd-gen platform’s immunogenicity in humans, this is a major inflection point for the story, and suggests potentially competitive mRNA platform relative to mRNA peers.

Following the data, CEO Franz-Werner Haas had said the company was starting the new year as a competitive player in mRNA therapies.

CureVac recently named its next CEO

In November, CureVac reported a near 62% year-over-year decline in its third quarter revenue. But Merle’s upgrade today suggests that she is bullish on the new management.

We note the stock is up ~50% since the data in Jan. But we think shares trade higher with more data/trial starts and as awareness builds for this under-the-radar mRNA story. We note additional Ph1 data is expected near-term.

Earlier this month, the biotech firm named Alexander Zehnder as its new Chief Executive. Zehnder, who’s currently the Global Head of Oncology at Sanofi, will assume the role on April 1st.

The biotech stock is still trading only at a fraction of its all-time high in February 2021.

Credit: Source link

ShareTweetSendPinShare
Previous Post

Here’s why crypto is yet to become a global payment option

Next Post

Ukraine says it’s time to review price cap on Russian oil

Related Posts

Google to launch its ChatGPT rival in the coming weeks
Trading

Google to launch its ChatGPT rival in the coming weeks

February 7, 2023
3
Wells Fargo sees a 50% upside
Trading

Wells Fargo sees a 50% upside

February 7, 2023
5
Market bear reveals his top pick for 2023
Trading

Market bear reveals his top pick for 2023

February 7, 2023
4
Dell announces layoffs to ‘be ready when the market rebounds’
Trading

Dell announces layoffs to ‘be ready when the market rebounds’

February 7, 2023
3
Best cryptos to buy now for February 2023
Trading

Wondering what crypto to buy now? 6 Play-To-Earn tokens to invest in early 2023

February 6, 2023
2
Next Post
Ukraine says it’s time to review price cap on Russian oil

Ukraine says it's time to review price cap on Russian oil

Recommended

Billionaire Jack Ma Is Giving Up Control of Ant Group

Billionaire Jack Ma Is Giving Up Control of Ant Group

January 7, 2023
4
10 Stocks with the Biggest Buybacks

10 Stocks with the Biggest Buybacks

January 15, 2023
4
Are housing costs out of reach in Canada for the average person? Absolutely 100%

Are housing costs out of reach in Canada for the average person? Absolutely 100%

January 24, 2023
5
Big Short Investor Michael Burry Sees This Asset Rising Amid FTX Contagion

‘Big Short’ Michael Burry Leaves Twitter After Advising Investors to Sell

February 3, 2023
5
The 2023 investment narrative is already diverging from 2022

The 2023 investment narrative is already diverging from 2022

January 19, 2023
5
Your Trading Edge Magazine

This is an online news portal that aims to share the latest news about trade, finance, crypto and much more. Feel free to get in touch with us!

What’s New Here!

  • Google to launch its ChatGPT rival in the coming weeks
  • Binance reportedly pausing USD deposits and withdrawals
  • These Crypto Companies to Send Aid Packages to Earthquake-Hit Turkey

Subscribe Now

Loading
  • Contact
  • Privacy Policy
  • Advertise With Us

© 2021 - ytemagazine.com - All rights reserved!

No Result
View All Result
  • Home
  • Feature
    • Market Commentary
    • Expert Advice
    • Columns
  • Trading
    • Shares and Trading
    • Technical Analysis
    • Trading Mindset
  • Crypto News
  • Finance
  • Subscribe

© 2021 - ytemagazine.com - All rights reserved!

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?